Closing the Loophole on Hemp-Derived Cannabis Products: A Public Health Priority

Alyssa F Harlow; Adam M Leventhal; Jessica L Barrington-Trimis

doi:10.1001/jama.2022.20620

Closing the Loophole on Hemp-Derived Cannabis Products: A Public Health Priority

JAMA. 2022 Nov 22;328(20):2007-2008. doi: 10.1001/jama.2022.20620.

Authors

Alyssa F Harlow¹, Adam M Leventhal¹, Jessica L Barrington-Trimis¹

Affiliation

¹ Department of Population and Public Health Sciences and Institute for Addiction Science, Keck School of Medicine, University of Southern California, Los Angeles.

No abstract available

Plain language summary

This Viewpoint discusses a federal policy loophole that allows psychotropic cannabis products to be commercially marketed and sold across the US, even in states where recreational cannabis is not legal.

MeSH terms

Cannabis*
Dronabinol
Hallucinogens
Health Priorities*
Medical Marijuana* / therapeutic use
Public Health Practice*

Substances

Dronabinol
Hallucinogens
Medical Marijuana

Grants and funding

R01 CA229617/CA/NCI NIH HHS/United States